Nivestim (Filgrastim)

Filgrastim binds to the specific cell‑surface receptor for granulocyte colony‑stimulating factor on hematopoietic progenitor cells in the bone marrow. This interaction triggers intracellular signaling pathways that promote proliferation, differentiation, and activation of neutrophil precursors, leading to increased production and release of mature neutrophils into the peripheral blood, thereby enhancing innate immune defense.

The prescribed dose of Nivestim is individualized by the treating physician based on the patient’s weight, the severity of neutropenia, and the clinical context such as chemotherapy regimen or transplant protocol. Dosing may be expressed in micrograms per kilogram or as a fixed daily amount, and the prescriber determines the exact schedule and duration.

Safety data for filgrastim in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their healthcare provider before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nivestim. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, cold‑chain shipping details, and necessary import documentation.

Nivestim contains the same recombinant filgrastim molecule found in other branded or biosimilar G‑CSF products. Clinical efficacy and safety are comparable when administered at equivalent doses. Differences may lie in manufacturing processes, packaging, or pricing, but the therapeutic effect of stimulating neutrophil recovery remains consistent across products.

Nivestim must be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F). It should be kept in its original carton to protect from light, must not be frozen, and should not be shaken. Before use, allow the product to reach room temperature if required, and discard any vial that shows particulate matter or discoloration.

Nivestim is supplied as a sterile solution for injection and can be given either subcutaneously or intravenously, depending on the clinical protocol. The injection is typically performed by a qualified healthcare professional using aseptic technique. The site of subcutaneous injection is usually the abdomen or thigh, and the volume administered is based on the prescribed dose.

Although generally well tolerated, serious adverse events can occur. These include splenic rupture, severe allergic reactions such as anaphylaxis, acute respiratory distress syndrome, capillary leak syndrome, and marked leukocytosis that may lead to vascular complications. Patients should be monitored closely for signs of these conditions, and treatment should be stopped if they arise.

Nivestim is contraindicated in individuals with known hypersensitivity to filgrastim or any of the product’s excipients. It should also be avoided in patients with a history of splenic rupture or severe sickle‑cell disease unless the benefits clearly outweigh the risks. Use in pregnant or lactating women is restricted to situations where the therapeutic advantage justifies potential fetal or infant exposure.